Chronic osteomyelitis due to Pseudomonas aeruginosa: treatment with elastomeric infusor in an outpatient setting
Chronic bacterial osteomyelitis requires long-term antibiotic treatment (at least 6-8 weeks). After in-hospital management, patients are usually discharged and treated in outpatient settings. However, when the aetiology is represented by Gram-negative microorganisms, outpatient treatment could be di...
Gespeichert in:
| Veröffentlicht in: | Le infezioni in medicina 2011-12, Vol.19 (4), p.257 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | ita |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 4 |
| container_start_page | 257 |
| container_title | Le infezioni in medicina |
| container_volume | 19 |
| creator | Carrega, G Bartolacci, V Burastero, G Casalino Finocchio, G Izzo, M Ronca, A Santoriello, L Tigano, S Riccio, G |
| description | Chronic bacterial osteomyelitis requires long-term antibiotic treatment (at least 6-8 weeks). After in-hospital management, patients are usually discharged and treated in outpatient settings. However, when the aetiology is represented by Gram-negative microorganisms, outpatient treatment could be difficult. Beta-lactam administration by means of an elastomeric infusor may represent an attractive approach. We report two cases of osteomyelitis due to Pseudomonas aeruginosa successfully treated with continuous ceftazidime administration via an elastomeric infusor in outpatient settings. In both cases the patients were free from clinical and laboratory signs of osteomyelitis at the end of treatment and after 12 months follow-up. |
| format | Article |
| fullrecord | <record><control><sourceid>pubmed</sourceid><recordid>TN_cdi_pubmed_primary_22212166</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>22212166</sourcerecordid><originalsourceid>FETCH-pubmed_primary_222121663</originalsourceid><addsrcrecordid>eNqFjkFqAkEQRXthUIleQeoCwnQrg-NWlCxduJdKptSS6a6hqxrx9plAXPs3b_N4_JGbeh_Wy2bVVBM3V71Xw-rKN81m7CYhBB98XU9dv7tlSfwDokYSn9SxsUJbCEzgqFRaiZJQASmXKydR3IJlQouUDB5sN6AO1SRSHjqcLkUlDwRMIMV6NP4zlcw4XWfu44Kd0vyfn25x2J92X8u-fEdqz33miPl5fl1cvRV-AUtmSls</addsrcrecordid><sourcetype>Index Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Chronic osteomyelitis due to Pseudomonas aeruginosa: treatment with elastomeric infusor in an outpatient setting</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Carrega, G ; Bartolacci, V ; Burastero, G ; Casalino Finocchio, G ; Izzo, M ; Ronca, A ; Santoriello, L ; Tigano, S ; Riccio, G</creator><creatorcontrib>Carrega, G ; Bartolacci, V ; Burastero, G ; Casalino Finocchio, G ; Izzo, M ; Ronca, A ; Santoriello, L ; Tigano, S ; Riccio, G</creatorcontrib><description>Chronic bacterial osteomyelitis requires long-term antibiotic treatment (at least 6-8 weeks). After in-hospital management, patients are usually discharged and treated in outpatient settings. However, when the aetiology is represented by Gram-negative microorganisms, outpatient treatment could be difficult. Beta-lactam administration by means of an elastomeric infusor may represent an attractive approach. We report two cases of osteomyelitis due to Pseudomonas aeruginosa successfully treated with continuous ceftazidime administration via an elastomeric infusor in outpatient settings. In both cases the patients were free from clinical and laboratory signs of osteomyelitis at the end of treatment and after 12 months follow-up.</description><identifier>ISSN: 1124-9390</identifier><identifier>PMID: 22212166</identifier><language>ita</language><publisher>Italy</publisher><subject>Anti-Bacterial Agents - therapeutic use ; Ceftazidime - therapeutic use ; Chronic Disease ; Diabetes Complications - drug therapy ; Diabetes Complications - microbiology ; Elastomers ; Equipment Design ; Follow-Up Studies ; Humans ; Infusion Pumps ; Infusions, Parenteral - methods ; Male ; Middle Aged ; Osteomyelitis - drug therapy ; Osteomyelitis - microbiology ; Outpatients ; Pseudomonas aeruginosa - drug effects ; Pseudomonas Infections - complications ; Pseudomonas Infections - drug therapy ; Risk Factors ; Treatment Outcome</subject><ispartof>Le infezioni in medicina, 2011-12, Vol.19 (4), p.257</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22212166$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Carrega, G</creatorcontrib><creatorcontrib>Bartolacci, V</creatorcontrib><creatorcontrib>Burastero, G</creatorcontrib><creatorcontrib>Casalino Finocchio, G</creatorcontrib><creatorcontrib>Izzo, M</creatorcontrib><creatorcontrib>Ronca, A</creatorcontrib><creatorcontrib>Santoriello, L</creatorcontrib><creatorcontrib>Tigano, S</creatorcontrib><creatorcontrib>Riccio, G</creatorcontrib><title>Chronic osteomyelitis due to Pseudomonas aeruginosa: treatment with elastomeric infusor in an outpatient setting</title><title>Le infezioni in medicina</title><addtitle>Infez Med</addtitle><description>Chronic bacterial osteomyelitis requires long-term antibiotic treatment (at least 6-8 weeks). After in-hospital management, patients are usually discharged and treated in outpatient settings. However, when the aetiology is represented by Gram-negative microorganisms, outpatient treatment could be difficult. Beta-lactam administration by means of an elastomeric infusor may represent an attractive approach. We report two cases of osteomyelitis due to Pseudomonas aeruginosa successfully treated with continuous ceftazidime administration via an elastomeric infusor in outpatient settings. In both cases the patients were free from clinical and laboratory signs of osteomyelitis at the end of treatment and after 12 months follow-up.</description><subject>Anti-Bacterial Agents - therapeutic use</subject><subject>Ceftazidime - therapeutic use</subject><subject>Chronic Disease</subject><subject>Diabetes Complications - drug therapy</subject><subject>Diabetes Complications - microbiology</subject><subject>Elastomers</subject><subject>Equipment Design</subject><subject>Follow-Up Studies</subject><subject>Humans</subject><subject>Infusion Pumps</subject><subject>Infusions, Parenteral - methods</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Osteomyelitis - drug therapy</subject><subject>Osteomyelitis - microbiology</subject><subject>Outpatients</subject><subject>Pseudomonas aeruginosa - drug effects</subject><subject>Pseudomonas Infections - complications</subject><subject>Pseudomonas Infections - drug therapy</subject><subject>Risk Factors</subject><subject>Treatment Outcome</subject><issn>1124-9390</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFjkFqAkEQRXthUIleQeoCwnQrg-NWlCxduJdKptSS6a6hqxrx9plAXPs3b_N4_JGbeh_Wy2bVVBM3V71Xw-rKN81m7CYhBB98XU9dv7tlSfwDokYSn9SxsUJbCEzgqFRaiZJQASmXKydR3IJlQouUDB5sN6AO1SRSHjqcLkUlDwRMIMV6NP4zlcw4XWfu44Kd0vyfn25x2J92X8u-fEdqz33miPl5fl1cvRV-AUtmSls</recordid><startdate>201112</startdate><enddate>201112</enddate><creator>Carrega, G</creator><creator>Bartolacci, V</creator><creator>Burastero, G</creator><creator>Casalino Finocchio, G</creator><creator>Izzo, M</creator><creator>Ronca, A</creator><creator>Santoriello, L</creator><creator>Tigano, S</creator><creator>Riccio, G</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope></search><sort><creationdate>201112</creationdate><title>Chronic osteomyelitis due to Pseudomonas aeruginosa: treatment with elastomeric infusor in an outpatient setting</title><author>Carrega, G ; Bartolacci, V ; Burastero, G ; Casalino Finocchio, G ; Izzo, M ; Ronca, A ; Santoriello, L ; Tigano, S ; Riccio, G</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-pubmed_primary_222121663</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>ita</language><creationdate>2011</creationdate><topic>Anti-Bacterial Agents - therapeutic use</topic><topic>Ceftazidime - therapeutic use</topic><topic>Chronic Disease</topic><topic>Diabetes Complications - drug therapy</topic><topic>Diabetes Complications - microbiology</topic><topic>Elastomers</topic><topic>Equipment Design</topic><topic>Follow-Up Studies</topic><topic>Humans</topic><topic>Infusion Pumps</topic><topic>Infusions, Parenteral - methods</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Osteomyelitis - drug therapy</topic><topic>Osteomyelitis - microbiology</topic><topic>Outpatients</topic><topic>Pseudomonas aeruginosa - drug effects</topic><topic>Pseudomonas Infections - complications</topic><topic>Pseudomonas Infections - drug therapy</topic><topic>Risk Factors</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Carrega, G</creatorcontrib><creatorcontrib>Bartolacci, V</creatorcontrib><creatorcontrib>Burastero, G</creatorcontrib><creatorcontrib>Casalino Finocchio, G</creatorcontrib><creatorcontrib>Izzo, M</creatorcontrib><creatorcontrib>Ronca, A</creatorcontrib><creatorcontrib>Santoriello, L</creatorcontrib><creatorcontrib>Tigano, S</creatorcontrib><creatorcontrib>Riccio, G</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><jtitle>Le infezioni in medicina</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Carrega, G</au><au>Bartolacci, V</au><au>Burastero, G</au><au>Casalino Finocchio, G</au><au>Izzo, M</au><au>Ronca, A</au><au>Santoriello, L</au><au>Tigano, S</au><au>Riccio, G</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Chronic osteomyelitis due to Pseudomonas aeruginosa: treatment with elastomeric infusor in an outpatient setting</atitle><jtitle>Le infezioni in medicina</jtitle><addtitle>Infez Med</addtitle><date>2011-12</date><risdate>2011</risdate><volume>19</volume><issue>4</issue><spage>257</spage><pages>257-</pages><issn>1124-9390</issn><abstract>Chronic bacterial osteomyelitis requires long-term antibiotic treatment (at least 6-8 weeks). After in-hospital management, patients are usually discharged and treated in outpatient settings. However, when the aetiology is represented by Gram-negative microorganisms, outpatient treatment could be difficult. Beta-lactam administration by means of an elastomeric infusor may represent an attractive approach. We report two cases of osteomyelitis due to Pseudomonas aeruginosa successfully treated with continuous ceftazidime administration via an elastomeric infusor in outpatient settings. In both cases the patients were free from clinical and laboratory signs of osteomyelitis at the end of treatment and after 12 months follow-up.</abstract><cop>Italy</cop><pmid>22212166</pmid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1124-9390 |
| ispartof | Le infezioni in medicina, 2011-12, Vol.19 (4), p.257 |
| issn | 1124-9390 |
| language | ita |
| recordid | cdi_pubmed_primary_22212166 |
| source | MEDLINE; EZB-FREE-00999 freely available EZB journals |
| subjects | Anti-Bacterial Agents - therapeutic use Ceftazidime - therapeutic use Chronic Disease Diabetes Complications - drug therapy Diabetes Complications - microbiology Elastomers Equipment Design Follow-Up Studies Humans Infusion Pumps Infusions, Parenteral - methods Male Middle Aged Osteomyelitis - drug therapy Osteomyelitis - microbiology Outpatients Pseudomonas aeruginosa - drug effects Pseudomonas Infections - complications Pseudomonas Infections - drug therapy Risk Factors Treatment Outcome |
| title | Chronic osteomyelitis due to Pseudomonas aeruginosa: treatment with elastomeric infusor in an outpatient setting |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-13T07%3A51%3A26IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Chronic%20osteomyelitis%20due%20to%20Pseudomonas%20aeruginosa:%20treatment%20with%20elastomeric%20infusor%20in%20an%20outpatient%20setting&rft.jtitle=Le%20infezioni%20in%20medicina&rft.au=Carrega,%20G&rft.date=2011-12&rft.volume=19&rft.issue=4&rft.spage=257&rft.pages=257-&rft.issn=1124-9390&rft_id=info:doi/&rft_dat=%3Cpubmed%3E22212166%3C/pubmed%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/22212166&rfr_iscdi=true |